Leadingtac Pharmaceutical
Focus: Leadingtac is a Series B-stage Chinese pharmaceutical company founded in 2019, focused on small-molecule development across neurology, cardiovascular, psychiatry, nephrology, and oncology. The company is currently monetized primarily through generic and near-LOE branded products.
Profile data last refreshed 12h ago · AI intelligence enriched 1w ago
Funding Stage
SERIES B
Open Jobs
0
About Leadingtac Pharmaceutical
AI assessmentNot HiringNo open roles listed right now. Follow Leadingtac Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Leadingtac Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$1M Part DDeclining
Post-LOE
Generic ANDA formulation generating minimal Part D spend; loss-of-exclusivity complete, representing tail-end monetization with no competitive moat.
Help build intelligence for Leadingtac Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.